
Kyorin Holdings Inc
TSE:4569

Kyorin Holdings Inc
Other Equity
Kyorin Holdings Inc
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Kyorin Holdings Inc
TSE:4569
|
Other Equity
ÂĄ190m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Other Equity
ÂĄ2.7T
|
CAGR 3-Years
70%
|
CAGR 5-Years
67%
|
CAGR 10-Years
18%
|
|
![]() |
Daiichi Sankyo Co Ltd
TSE:4568
|
Other Equity
ÂĄ263.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
5%
|
|
![]() |
Otsuka Holdings Co Ltd
TSE:4578
|
Other Equity
ÂĄ336.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
![]() |
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Other Equity
ÂĄ11.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
21%
|
|
![]() |
Astellas Pharma Inc
TSE:4503
|
Other Equity
ÂĄ521.6B
|
CAGR 3-Years
28%
|
CAGR 5-Years
37%
|
CAGR 10-Years
11%
|
Kyorin Holdings Inc
Glance View
KYORIN Holdings, Inc. engages in the development, manufacture and sale of pharmaceutical products through its subsidiaries. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 2,243 full-time employees. The company went IPO on 2006-03-10. The firm operates through two business segments. The Pharmaceuticals segment is engaged in the manufacture, purchase and sales of pharmaceutical products, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, as well as the research of new drugs and candidate compounds. The company also engages in the purchase and sales of medical promotion tools and packaging materials. The Healthcare segment is engaged in the manufacturing, sales and purchase of environmental sanitation products, general purpose medicines and skin care products.

See Also
What is Kyorin Holdings Inc's Other Equity?
Other Equity
190m
JPY
Based on the financial report for Dec 31, 2024, Kyorin Holdings Inc's Other Equity amounts to 190m JPY.